Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

New data expands on findings shared at ATTD and reinforces Eversense 365’s strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year

GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals sustained accuracy, performance and positive impact of Eversense 365 in both open-loop and closed-loop systems. The findings were presented during an oral presentation entitled ‘Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System’ at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place on June 5-8 in New Orleans, U.S.   

The data presented at ADA expands on the findings Senseonics previously shared at the 19^th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) earlier this year, with a dataset including more sensors and users of Eversense 365, the first and only one year CGM- system. The presentation highlighted a real-world analysis of the first 12,360 Eversense 365 CGM sensors among open-loop users and an additional 153 closed-loop users, with the CGM used as part of the twiist Automated Insulin Delivery (AID) system for more than 30 days.

The extended dataset confirms the positive real-world impact of Eversense 365, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes. Importantly, the system delivered comparable adherence and outcomes between the first and second six-month period, indicating high accuracy and performance from a single sensor across an entire year. The presentation also highlighted strong glucometrics of the Eversense 365 and twiist combination, suggesting that the first ever AID integration with this unique CGM is having a meaningful clinical impact for people living with diabetes.  

Schreibe Deinen Kommentar